Key Takeaways:
A class-action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) after the company revealed trial failures that caused its stock to drop 7.77% in a single day.
"Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies," the complaint filed by Bronstein, Gewirtz & Grossman, LLC, alleges.
The lawsuit centers on Nektar's REZOLVE-AA trial for its lead product candidate, rezpegaldesleukin. According to the filings, the company failed to disclose that patient enrollment did not follow trial protocols, which was likely to negatively impact the results. On December 16, 2025, Nektar announced the trial had failed to reach statistical significance, a failure it attributed to the inclusion of four patients who should not have been eligible. The company's stock fell $4.14 per share to close at $49.16 on the news.
The legal action creates significant risk for the biopharmaceutical company, with multiple law firms including The Schall Law Firm, Rosen Law Firm, and Robbins LLP publicizing the case. Investors who purchased securities between February 26, 2025, and December 15, 2025, are included in the class. The deadline to file as a lead plaintiff is May 5, 2026.
The lawsuits seek to recover damages for investors who suffered losses due to the allegedly false and misleading statements. While a class has not yet been certified, investors who purchased shares during the class period may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement.
This legal battle puts Nektar's stock, which had already been under pressure, in a more precarious position. The outcome of the lawsuit could have significant financial implications for the company. Investors will be closely watching for the company's response to the allegations and any developments in the case ahead of the May 5, 2026, lead plaintiff deadline.
This article is for informational purposes only and does not constitute investment advice.
